



## Community Behavioral Health: Provider Notification Long-Acting Injectables Toolkit October 25, 2017

Long-acting injectables (LAI) have been shown through research to 1) improve adherence, 2) reduce frequency of symptom relapse, 3) reduce re-hospitalization, and 4) improve treatment outcomes for individuals who struggle with adherence to antipsychotic medication. Despite this evidence, LAIs remain an underutilized option for individuals receiving mental health treatment. To increase ease of access to LAI and related supports, CBH has assembled the Long-Acting Injectables Toolkit for providers who work with individuals prescribed antipsychotics. This Toolkit was presented to providers who participated in the LAI Webinar on 9/27/17 and is being shared under CBH Resources on DBHIDS website and via [this link](#). The CBH LAI Toolkit is intended to equip providers to facilitate seamless transitions for individuals from inpatient to community settings. The Toolkit includes:

### Long-Acting Injectables Toolkit

- [LAI Toolkit Fact Sheet](#)
- [LAI Referral Flow](#)
- [LAI FAQ](#)
- [LAI Toolkit Webinar](#)
- [LAI Referral Form](#)
- [MCO Crosswalk](#)
- [Outpatient CIRC Contact](#)
- [Case Management Application](#)
- Prior Authorization Forms
  - [Aetna Generic Prior Auth](#)
  - [Aetna LAI-Antypshychotics](#)
  - [HPP Abilify Maintena PA](#)
  - [HPP Invega-Sustenna PA](#)
  - [HPP Invega-Trinza PA](#)
  - [HPP Risperdal-Consta PA](#)
  - [Keystone First LAI PA](#)
  - [United Atypical Antipsychotic PA](#)

Please direct any questions related to LAIs or the Toolkit to Jeffrey Sensenig at [jeffrey.sensenig@phila.gov](mailto:jeffrey.sensenig@phila.gov) or 267-602-2073.